The aim of this article is to outline the initial development of histotripsy, a noninvasive image-guided focused ultrasound technology that mechanically homogenizes targeted tissues and to describe the results of preclinical translational research directed toward urologic applications.
INTRODUCTION
Histotripsy is an experimental focused ultrasound technology in which acoustic energy generated by an extracorporeal transducer is focused on a target volume inside the body. Conceptually, histotripsy is more similar to shockwave lithotripsy (SWL) than to high intensity focused ultrasound (HIFU). Histotripsy was initially conceived and developed at the University of Michigan; so much of the refinement and preclinical translation has originated from these laboratories. More recently, other groups have begun to experiment with histotripsy both along technical and translational lines of research, which serves to validate the concept of histotripsy and further enrich the potential therapeutic value of this new technology.
SCIENTIFIC BACKGROUND
Histotripsy is defined as delivery of acoustic energy in the form of short (<50 ms) very high intensity pulses, which induces controlled cavitation to mechanically homogenize targeted tissue [1] . Cavitation is a process that occurs when a sufficiently negative pressure is applied to a fluid (or in this case tissue) to cause microbubble formation from fluid vaporization and release of dissolved gas [2] . Once formed, the microbubbles exhibit highly dynamic patterns of oscillation and inertial collapse, which impart severe stresses on surrounding cells and tissues and produces cellular and tissue disruption [3] .
To characterize this process of tissue homogenization, increasing numbers of histotripsy pulses from a 750 kHz piezoelectric transducer were applied in an in-vivo rabbit model [4] . Ten pulses produced sparse, scattered focal hemorrhage containing some cellular debris. With additional pulses, these small foci of homogenized tissue enlarged and merged with adjacent foci to 'fill in' the geometric focal volume, ultimately producing a liquefied core of cytoplasm and fractionated cellular material surrounded by a smooth boundary [4, 5] . After 1000 pulses, this process appears to be self-limited as there was no apparent difference between lesions created with 1000, 10 000, or greater number of pulses [4] . The efficiency of this process can be increased using techniques to remove the bubble nuclei, which persist between pulses [6] .
Grossly and microscopically, the appearance of histotripsy treated tissue is distinct from thermally ablated tissue. In an ex-vivo porcine kidney model, thermocouples were placed at tissue target points treated with a wide range of acoustic parameters that included those used for histotripsy and HIFU [7] . Lesions characterized as disrupted (in which liquefied material spilled out of a cavity after sectioning) corresponded to sonications in which tissue temperature increase was less than 27 degrees C. Desiccated lesions were associated with sonications in which tissue temperature increased 40 degrees C or greater. These results confirmed that histotripsy can be produced by selecting parameters that isolate cavitational mechanical effects and minimize thermal tissue deposition [7] . This has recently been validated with 'boiling histotripsy' a related technology that induces spatially and temporally localized superheating of mm-sized tissue volumes to produce microbubbles, which then exhibit histotripsy behavior and produce mechanical homogenization [8 & ,9] . The biological response to tissue treated with histotripsy is different than the response to thermal tissue coagulation. In an in-vivo rabbit model, histotripsy was applied to kidneys, which were then harvested 1-60 days after treatment [10] . The resultant homogenized debris was resorbed within 45-60 days with very little deposition of fibrotic tissue scar formation [10] . In separate canine studies, the liquid consistency of the tissue after prostate histotripsy facilitated drainage via the urethra and produced an effective debulking of the prostate [11, 12, 13 && ]. The microbubble clouds responsible for tissue homogenization are excellent sound reflectors and appear as hyperechoic (bright) zones with ultrasound imaging ( Fig. 1 ) [1, 4] . This feature allows accurate target colocalization and provides real-time ultrasound monitoring of treatment progression. Following histotripsy treatment, fractionated tissue appears hypoechoic as many of the structures that would have reflected ultrasound energy have been broken down and homogenized [4, 11] . Ultrasound backscatter assessment and shear wave imaging have been studied as methods to better indicate the degree of tissue homogenization during histotripsy treatment [14] [15] .
A unique feature of histotripsy is the high precision with which tissue bioeffects can be confined within a targeted volume. Using a phantom prostate composed of red blood cells and agar, histotripsy was applied in the pattern of a 'plus' sign. Cavitation activity lyses the red blood cells, which change color. This color change is readily apparent and serves as a marker of histotripsy mechanical effect ( Fig. 2) [16] . The straight lines and right angle corners created are indicative of the precision achievable with histotripsy ablation. An even
KEY POINTS
Histotripsy is an image-guided noninvasive nonthermal focused ultrasound therapy that induces and controls cavitation to homogenize targeted tissue within the body.
The nonthermal mechanism of action of histotripsy allows precise ablation with conversion of tissue to a liquefied homogenate. Real-time ultrasound monitoring of the bubble cloud confirms targeting and provides assessment of treatment progression.
Preclinical translation research has been published on histotripsy treatment of benign prostatic hyperplasia (BPH), prostate cancer, renal masses, renal stones, and ureteroceles.
Histotripsy is a platform technology with many additional potential therapeutic applications within and beyond urology. greater level of precision is possible by applying preconditioning pulses to delete bubble nuclei at the periphery of the targeted volume before delivery of histotripsy pulses [17] .
HISTOTRIPSY FOR BENIGN PROSTATIC HYPERPLASIA
Histotripsy is an intriguing technology to apply to BPH. Potential advantages include energy application from an extracorporeal source with real-time transrectal ultrasound (TRUS) image-guidance, nonthermal tissue homogenization, and liquefaction, which facilitates drainage of debris via the urethra, and rapid debulking of the prostate. To explore and understand the potential of histotripsy as a therapy for BPH, a canine model (intact older male dogs) was utilized for its anatomic similarity to the human prostate and urethra. Histotripsy was applied transabdominally by positioning anesthetized canines supine and placing a water bolus over the suprapubic region. The histotripsy transducer was coupled to the canine through the water bolus and its focal volume targeted on the prostate. A 10 MHz TRUS imager provided high-resolution images of the prostate for targeting and observation of the bubble cloud ( Fig. 3 ). Volume ablation of glandular and prostatic urethral tissue was accomplished by moving the bubble cloud (by changing the position of the histotripsy transducer) along a preprescribed grid pattern or by manipulation of joystick controls guided by TRUS image feedback.
Once the feasibility of prostate histotripsy was established in acute individuals [11] , it became apparent that glandular tissue was more easily homogenized than periurethral prostatic tissue (28 000 versus 270 000 pulses/cm 3 ) [12] . In a subsequent study, the endoscopic appearance of the prostatic urethra was assigned a score immediately after histotripsy. This score was found to correlate with the probability of disintegration of the prostatic urethra by 14 days, which allowed drainage of homogenate from the treatment cavity via the urethra [18] . An alternative treatment strategy, targeting a modest 1-2 cm 3 volume of glandular tissue with histotripsy and sparing periurethral tissue, produced pools of homogenized debris that . Experimental histotripsy apparatus in use during canine prostate treatment. A power supply and driving electronics (left) provide power to the histotripsy transducer, which is suspended over the suprapubic region of the canines in a bath of degassed water. The histotripsy transducer is positioned so that the focal volume is within the prostate. A transrectal ultrasound probe is inserted in the rectum to provide imaging of the prostate and bubble cloud during treatment.
generally resorbed over 8 weeks. Prostate volume was decreased 12% at harvest, and most treatment cavities contained simple fluid. There was no evidence of abscess or increased chronic inflammation in the prostates [19 & ]. In all of the previous experiments, very little hemorrhage was observed. To further explore this finding, nine canines were administered warfarin (international normalized ratio 1.2-11.3), and then aggressive histotripsy of the prostate was performed to create a TURP-like defect [20] . Mild hematuria without clots was observed during the first 48 h after treatment. Serial assessment of hemoglobin did not demonstrate significant change, suggesting that the mechanical action of histotripsy may also be inducing hemostatic effects even in the setting of anticoagulation with warfarin.
Local and systemic effects of histotripsy were studied in 18 canines that underwent treatment of at least a 4 cm 3 volume of prostate tissue encompassing glandular tissue and prostatic urethra. Prostates were harvested at time points between 0 and 56 days after treatment, and in each case tissue homogenization or a drained treatment cavity were apparent. Mild post-treatment discomfort resolved with catheter removal. When the rectum was inadvertently treated on several occasions, tissue effects were apparent at harvest, and in one case a prostatorectal fistula developed. Otherwise, only minimal hematuria and transient post-treatment abnormalities in blood tests were observed [13 && ]. Urothelialization of the treatment cavity with minimal residual debris was seen 28 days after treatment ( Fig. 4) . On the basis of this study, it appeared that histotripsy when properly targeted in the prostate was safe and well tolerated in the canine model.
Although histotripsy can create precise lesions in the ideal setting (phantom), targeting errors or patient motion in the in-vivo setting may expose adjacent structures to histotripsy and potential injury. It was apparent in earlier research that thresholds for damage from histotripsy vary based on tissue characteristics [12, 21] . To establish the thresholds for damage of critical periprostatic structures, two studies [22,23 & ] were conducted applying histotripsy (1000, 10 000, or 10 0000 pulses) directly to the urinary sphincter, neurovascular bundle, rectum, and 750 000 pulses to the bladder trigone and ureteral orifices. The rectum exhibited the greatest susceptibility for damage with 10 000 pulses causing moderate collagen disruption and focal mucosal homogenization. The other structures, however, appeared quite resilient to histotripsy damage. After 10 0000 pulses, the urinary sphincter was structurally intact and exhibited minimal histologic muscle fiber disruption. Arteries, veins, and nerves within the neurovascular bundles appeared intact, although extensive homogenization was apparent in surrounding loose connective tissue [22] . Cystoscopy after direct histotripsy treatment revealed edema of the bladder trigone. One of 12 renal units exhibited transient hydronephrosis in follow-up, although at harvest all ureteral orifices were cannulated and found to be patent [23 & ]. Histologically, only localized pockets of mild fibrosis were evident and deemed to be clinically insignificant.
To determine the best acoustic path to the human prostate, abdominal pelvic computed tomography data sets from 17 human individuals were analyzed. Three dimensional reconstructions of the pelvic bony anatomy and prostate were used to back project from the prostate to the therapy transducer located in either a perineal or suprapubic location. The perineal approach was superior, allowing an average unblocked transducer surface area of 77.0, 94.4, and 99.6% when targeting the base, middle, and apex of the prostate [24] . A transrectal approach is used by commercial prostate HIFU systems and would also simplify targeting and energy delivery with histotripsy. This is not yet feasible with current piezoelectric technology as the transducer surface area needed to initiate acoustic cavitation is larger than can be practically inserted in the rectum. However, future evolution of piezoelectric technology will likely make transrectal histotripsy practical. In order to translate histotripsy from the research laboratory to human use, HistoSonics, Inc. was formed in December 2009. Subsequently, a human prototype device (VortxR X ) was created for the treatment of BPH, and in May 2013 the US Food and Drug Administration approved a human pilot trial.
HISTOTRIPSY FOR PROSTATE CANCER
Much of the preclinical work applying histotripsy to the prostate as reviewed in the previous section is also applicable to development of histotripsy as a focal therapy modality for prostate cancer treatment. To further explore histotripsy treatment of prostate cancer, a unique canine ACE-1 prostate cancer model with metastatic potential was developed [25] . Utilizing this ACE-1 prostate tumor model, 10 canines were implanted with tumor cells [26 && ]. Discrete tumors were identified by TRUS 2 weeks later in all individuals. In seven canines, histotripsy was applied and created a bubble cloud, which was translated through a portion of the targeted tumors within the prostate using real-time TRUS feedback. Four prostates were harvested acutely and three at 2-3 weeks after treatment. Tumor homogenization was apparent in all acute individuals, whereas histology from chronic individuals revealed necrosis and hemorrhage. Metastases were apparent in all three tumor implanted controls, whereas none of the histotripsy treated chronic individuals exhibited metastases [26 && ]. This work demonstrated initial feasibility of histotripsy treatment of implanted ACE-1 tumor in canine prostate and suggests that real-time TRUS-guided histotripsy may have utility as a prostate focal therapy. Additional larger studies are being designed to more extensively examine completeness of local tumor ablation, systemic response, and further characterization of metastatic burden after histotripsy.
HISTOTRIPSY FOR RENAL MASSES
Research is also being conducted applying histotripsy for the treatment of small renal masses. Feasibility of extracorporeal histotripsy ablation of renal tissue was confirmed in an in-vivo rabbit model with rapid resorption of the homogenized debris and minimal scar formation [4, 10] . To assess treatment effect on malignant tissue, 2-mm 3 cubes of VX-2 tumor from a donor rabbit were implanted below the renal capsule in 15 rabbits. Two weeks after implantation, malignant masses were discernable with transcutaneous ultrasound imaging and treated by translating the bubble cloud through a portion of the tumor mass under ultrasound guidance. Histology from acute specimens demonstrated pools of homogenized tumor, while kidneys harvested at 24 h after treatment also exhibited an acute inflammatory response [27] . This study confirmed malignant tissue in the kidney could be homogenized with histotripsy and led to the next set of experiments to measure the metastatic burden after histotripsy.
Concerns have previously been raised (based on studies of other modalities with cavitation potential) that application of acoustic energy to malignant tissues could disrupt the structure of a tumor and its cellular attachments and increase downstream metastases. To assess whether these same concerns apply to histotripsy, aggressive VX-2 tumor was implanted in the left kidneys of New Zealand White rabbits [28 & ]. Histotripsy was applied to a portion of the implanted tumors 13 days after implantation, followed by nephrectomy the following day, and necropsy 1 week later. Successful treatment was confirmed by the presence of homogenized material adjacent and within residual implanted tumor in all cases. No statistical difference in total lung metastases or metastatic density was found between treated and control rabbits [28 & ]. Similar results have been seen in a murine model using mechanical HIFU, a form of ultrasound therapy in which both thermal and cavitational effects are induced [29] . Research is ongoing to more explicitly measure circulating tumor cells and time course of metastatic implants following histotripsy therapy in several other aggressive tumor models.
HISTOTRIPSY FOR RENAL STONES
Histotripsy therapy is based on the isolation and control of cavitation in order to homogenize targeted tissue. Cavitation is also known to play a role in SWL treatment of urinary stones. The feasibility of using histotripsy for the treatment of renal stones was tested in a tank study with Ultracal-30 model stones. Histotripsy was found to erode stones at a rate of 88 mg/min compared with 110 mg/min achieved with a piezoelectric lithotripter [30, 31] . However, histotripsy produced particles no larger than 100 mm compared with the range of fragment sizes produced by SWL [30, 31] . These results highlight a distinction between two methods of stone comminution. Histotripsy (pure cavitation) is efficient at erosion, whereas SWL predominantly produces a progressive stone subdivision. This led to the hypothesis that potential synergies could be exploited between SWL and histotripsy to enhance treatment of urinary stones. An apparatus was constructed that incorporated both an electrohydraulic shock wave source and a histotripsy transducer colocalized on model stones. Application of both histotripsy and SWL pulses produced more efficient stone comminution, and a fragment distribution shifted toward smaller sizes than SWL alone [32 & ]. Histotripsy appeared to pit the stone surface, which enhanced SWL-induced crack propagation, whereas the sequential stone subdivision resulting from SWL provided a greater surface area for histotripsy stone erosion [32 & ]. Further studies are underway to control and/or eliminate residual bubble nuclei, which act to shield the stone from incoming acoustic energy. Better control of bubble behavior adjacent to the stone may allow substantial improvement in efficiency of histotripsy and SWL pulses. These optimizations, if validated in in-vivo models, are envisioned to shorten therapy time, allow treatment of larger stones, and minimize size and volume of stone fragments.
OTHER HISTOTRIPSY APPLICATIONS
Other urologic applications of histotripsy include erosion of ureteroceles in an ex-vivo tissue model [33 & ] and in-vitro histotripsy destruction of Escherichia Coli biofilms that can frequently coat indwelling urinary catheters and stents [34] . Histotripsy has also been evaluated as a noninvasive therapy for other nonurologic diseases. Transcutaneous liver ablation in an in-vivo porcine model has been shown feasible and appears promising for the treatment of hepatocellular carcinoma and other liver malignancies [35 & ]. Creation of intracardiac ventricular septal communications, initially conceived as a method to palliate congenital heart defects, has been successful in a porcine model without deleterious effects up to 1 month after treatment [36 && ]. Fetal intervention with histotripsy has been evaluated in a fetal sheep model. Intrauterine histotripsy ablation of renal and liver tissue was successful and appeared to have no developmental impact when necropsy examination was performed after birth [37 && ]. This raises a number of possibilities for in utero treatment of urologic conditions including posterior urethral valves and ureteropelvic junction obstructions. Histotripsy has been utilized to homogenize deep venous thrombosis and re-establish venous flow without damaging the walls of femoral veins in an in-vivo porcine model [38] . Additionally, histotripsy has been used to create an acoustic embolus trap in phantom blood vessel models, which could prove useful in conjunction with acoustic or other forms of thrombolysis [39 & ].
CONCLUSION
Histotripsy is a unique image-guided, focused ultrasound nonthermal ablative technology that relies upon initiation of acoustic cavitation to mechanically homogenize targeted tissue. Histotripsy research originated from the University of Michigan but has now spread to other academic and research institutes as well. The extracorporeal delivery of energy, homogenization of tissue, and real-time monitoring of the ablation process are unique features with potential impact on improved patient tolerability and immediate confirmation of treatment adequacy. Preclinical exploration is ongoing for a number of urologic and nonurologic applications and has progressed to a human pilot trial for the treatment of BPH.
Park S, Maxwell AD, Owens GE, et al. Noninvasive embolus trap using histotripsy: an acoustic parameter study. Ultrasound Med Biol 2013; 39:611-619. This study demonstrates the ability of histotripsy to trap emboli in a model vessel with flow. This may be an important adjunct when histotripsy is applied for thrombolysis.
